`
`THE INHIBITORY EFFECT OF SODIUM n-DIPROPYL ACETATE ON THE
`DEGRADATIVE ENZYMES OF THE GABA SHUNT
`
`Department of Neurochemistry,
`
`Institute ofNeurology, London, WCI and *Department
`Imperial College, London, SW 7 2AZ UK
`
`of Biochemistry,
`
`2. Materials and methods 2.1.
`
`SSAD and SSA preparation and assay
`SSAD
`
`GABATpreparation and assay
`
`Received 14 February 1975 1. Introduction GABA may well be a major inhibitory transmitter in the mammalian CNS [l] and agents which inhibit its synthesising enzyme glutamate decarboxylase usually lower brain GABA levels and cause seizures [ 21. Conversely, agents which raise brain GABA levels usually protect against convulsions. The latter com- pounds may well act by inhibiting the GABA degrading enzymes GABAT and SSAD. One such agent is sodium n-dipropyl acetate, the salt of an 8-carbon branched fatty acid, which is a recently introduced clinical anticonvulsant [3]. It has been shown to produce a 30-40% elevation of total brain GABA following a single intraperitoneal injection into mice, and the time of peak elevation of GABA corresponds to the time of maximum protection against seizures [4]. Following the extraction of brain GABAT and its assay in the presence of dPA, these authors have concluded that the rise in GABA concentration results from the inhibition of this enzyme. However, since the metabolic route of GABA degradation involves two enzymes, namely GABAT and SSAD, the possibility arises that more than one enzyme is inhibited by dPA. This paper reports an inhibition of SSAD by dPA which appears to be more potent than its action on GABAT.
`was prepared from guinea pig kidney accord- ing to the method of Pitts et al. [5], and from rat brain by the method of Kammeraat and Velstra [6] . SSA was prepared by the method of Langheld [7] as modified by Bruce et al. [8] . A higher yield was obtained if the sodium hypochlorite and sodium glutamate were incubated for 60 min as opposed to the original 10 to 15 min. SSAD was assayed by the method of Kammaraat [6], the rate of reduction of NAD being followed fluorimetrically. The SSA preparations were assayed against standard NADH by employing SSAD. 212.
`Partially purified GABAT was prepared from rat brain by Fowler’s method [9], except that Triton X-l 00 was omitted from the initial homogenising medium as it interfered with the subsequent assay. Maximal activation of the enzyme was obtained instead by exposing the crude homogenate to ultra- sound (15 kI-Iz; 8 /.J amplitude; stainless steel probe) for six bursts of 30 set with cooling for 3 min between each exposure. The enzyme was assayed by the method of Balazs et al. [ lo] . This employs the transamination of SSA with glutamate to produce GABA, and the 2- oxoglutarate generated is reduced by glutamate dehydro- genase in the presence of excess ammonium ion. As the SSA preparation contained 2-oxoglutarate as an impurity, the reaction mixture was preincubated, in the absence of GABAT, and with excess NADPH (0.16 mM) for 10 min at room temperature to convert this 2-oxoglutarate to glutamate before starting the 251
`
`Abbreviations:
`
`n
`
`- dipropylacetate; GABA: y-amino butyric acid; GABAT: 4 amino-butyrate 2-oxogluta- rate transminase (EC 2.6.1.19); SSA: Succinic semialdehyde: SSAD; Succinic semialdehyde dehydrogenase; OAAA: oxy- aminoacetic acid.
`
`North-Holland Publishing Company - Amsterdam
`
`PAR1029
`IPR of U.S. Patent No. 8,772,306
`Page 1 of 4
`
`P. K. P. HARVEY, H. F. BRADFORD* and A. N. DAVISON
`dPA: Sodium
`
`
`Volume 52, number 2 FEBSLETTERS April 1975 L V
`
`.
`
`,
`20
`
`I
`5
`
`I
`IO
`
`f
`
`I IQ’S
`
`Fig.1. Regression lines for Lineweaver-Burk plots for SSAD: (0) SSA alone; (a) in the presence of 5 mM dPA; (A) in the presence of 10 mM dPA. V is in arbitrary fluorometric units. Each point is the mean of between 6 and 10 experiments. A)Rat brain SSAD. SSA concentrations: 4 X 10e6 M-5 X lo-’ M. K, (apparent) for SSA is 1 X lo-’ M. B) Guinea pig kidney SSAD. SSA concentrations: 6 X lo-‘M-5 X lo-’ M. K,,, (apparent) for SSA 8.6 X lo-’ M. 252
`
`PAR1029
`IPR of U.S. Patent No. 8,772,306
`Page 2 of 4
`
`
`
`by
`
`SSAD inhibition
`
`Conventional Lineweaver-Burk plots of k against f produced on apparent
`K,
`
`1 X IO-’ M OAAA, a specific inhibitor of GABAT [9]. Glutamate dehydrogenase was not inhibited by dPA. 3. Results 3.1.
`of 1 .O X lo-’ M for brain SSAD, and 8.6 X 10m6 for the kidney enzyme (fig.1). Both were substantially and significantly inhibited by dPA (5 and 10 mM), with an apparent Ki of approxi- mately 1.5 X 10m3 for brain and 0.5 X 10e3 M for kidney. 3.2.
`
`Volume 52, number 2 FEBS LETTERS April 1975 f ’ Ki JPA
`of 6 X 10m3 M. Although the data of fig.3 suggest an apparently competitive inhibition of GABAT by dPA with respect to SSA, and a non- competitive inhibition with respect to glutamate, analysis shows that there is no significant difference between the respective regression lines. It appears, therefore, that dPA is having little or no effect on the activity of this enzyme. 4. Discussion The above results demonstrate that SSAD from rat brain and from guinea pig kidney is more potently inhibited by dPA than is GABAT from rat brain. It is therefore probable that SSAD provides the pri- mary site of action of dPA in the GABA shunt path- way of brain. The effect of dPA on GABAT reported by Simler et al. [4] is probably due to an effect on SSAD; which, although initially present in their assay in excess, could have become rate-limiting following its inhibition by dPA. Maitre et al. [ 1 l] , from the same laboratory, have examined the inhibition of GABAT by two analogues of dPA using a technique in which
`
`'M. B) Guinea pig kidney SSAD. SSA concentrations: (0) 1.7 X 10ms M, (e) 1.3 X 10e5 M, SSA is chemically measured, and not assayed enzy (A) 0.8 X lo-’ M, (7) 0.7 X lo-’ M. Ki is approximately mically employing SSAD. Although these analogues 0.5 x 10-s M. were effective inhibitors of GABAT, the data given 253 assay by addition of GABAT. The GABAT preparation showed no SSAD activity and was totally inhibited
`
`GABA T activity
`The
`Km
`GABAT extracted from brain displayed an apparent
`
`n'i
`
`JPA
`
`Fig.2. Determination of approximate Ki for inhibition of SSAD by dPA. V is in arbitrary fluorometric units, dPA concentrations in mM. A) Rat brain SSAD. SSA concen- trations: (0) 4 X 10e6 M, (m) 2 X 10e6 M, (A) 1 X lo-’ M. Ki is approximately 1.5 X
`
`lo-
`
`PAR1029
`IPR of U.S. Patent No. 8,772,306
`Page 3 of 4
`
`
`
`Volume 52, number 2 FEBS LETTERS April 1975 A I 0.2 , @4 I.0 2.0 I GlutaItIate J.s.r. Fig.3. Regression lines for Lineweaver-Burk plots for GABAT. Each point is the mean of at least six experiments. A) SSA. 1.7 x lo-’ M. (0) Glutamate 20 X low3 M-2.5 X 1Om3 M, (=I with 10 mM dPA. The difference between the two regression tines is not significant (P>O.OS). B) Glutamate 10 X 10m3 M. (0) SSA 1.7 X 10e3 M-O.34 X 10e3 M, (9) with 10 mM dPA. Difference between two regression lines is not significant. (P>O.l). for dPA suggests a Kj value of 18 X 10m3 M. The coincidence of peak GABA levels with the maximum anticonvulsant effect of dPA suggests a direct causal link between the two. However, raised intracellular GABA concentration will not necessarily lead to raised GABA levels at inhibitory receptors, and demonstrating a changed compartmentation of GABA in favour of an extracellular location is likely to be of more significance in the mode of action of dPA. Acknowledgement We are grateful to Reckitt and Coleman Pharmaceu- tical Division for their generous financial assistance.
`[l] Krnjevik, K. (1974) Pharm. Rev. 26(n), 448-457. [ 21 Wood, J. D. and Peesker, S. J. (1974) J. Neurochem. 131 141 [51 [61 [71 [81 191 [lOI [Ill 23,703-712. Jeavons, P. M. and Clarke, J. E. (1974) Brit. Med. J. ii, 584-586. Simler, S., Ciesielski, L., Maitre, M., Randrianarisoa, H. and Mandel, P. (1973) Biochem. Pharmac. 22, 1701-1708. Pitts, F. N., Quick, C. and Robins, E. (1965) J. Neurochem. 12, 93-101. Kammeraat, C. and Veldstra, H. (1968) Biochim. Biophys. Acta. 151, I-10. Langheld, K (1909) Ber. 42, 392 and 2360. Bruce, R., Sims, K., Pitts, F. N. (1971) Anal. Biochem. 41, 271-273. Fowler, L. J. and John, R. A. (1972) Biochem. J. 130, 569-573. Balazs, R., Dahl, D. and Harwood, J. R. (1966) J. Neurochem. 13, 897-905. Maitre, M., Ciesielski, L. and Mandel, P. (1974) Biochem. Pharmac. 23, 2363-2368. 254
`
`References
`
`PAR1029
`IPR of U.S. Patent No. 8,772,306
`Page 4 of 4
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ ChargeStill Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site